Sumitomo Mitsui Trust Group Inc. Has $615,000 Stock Holdings in COMPASS Pathways PLC Sponsored ADR $CMPS

Sumitomo Mitsui Trust Group Inc. lowered its stake in COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS) by 4.6% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 219,651 shares of the company’s stock after selling 10,479 shares during the period. Sumitomo Mitsui Trust Group Inc. owned 0.23% of COMPASS Pathways worth $615,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Nantahala Capital Management LLC lifted its stake in shares of COMPASS Pathways by 182.9% in the 1st quarter. Nantahala Capital Management LLC now owns 2,829,232 shares of the company’s stock valued at $8,092,000 after acquiring an additional 1,829,232 shares during the last quarter. Vivo Capital LLC grew its position in COMPASS Pathways by 109.1% during the 1st quarter. Vivo Capital LLC now owns 3,362,385 shares of the company’s stock worth $9,616,000 after acquiring an additional 1,754,385 shares during the last quarter. Woodline Partners LP increased its holdings in COMPASS Pathways by 279.9% in the 1st quarter. Woodline Partners LP now owns 1,754,856 shares of the company’s stock worth $5,019,000 after purchasing an additional 1,292,927 shares in the last quarter. Driehaus Capital Management LLC acquired a new position in COMPASS Pathways in the 1st quarter worth about $2,007,000. Finally, 22NW LP bought a new position in COMPASS Pathways in the first quarter valued at about $1,849,000. Institutional investors own 46.19% of the company’s stock.

COMPASS Pathways Stock Up 0.3%

COMPASS Pathways stock opened at $6.32 on Friday. The firm has a market cap of $606.34 million, a price-to-earnings ratio of -3.43 and a beta of 2.21. COMPASS Pathways PLC Sponsored ADR has a 52-week low of $2.25 and a 52-week high of $7.09. The company has a debt-to-equity ratio of 0.16, a quick ratio of 8.82 and a current ratio of 8.82. The firm has a 50 day moving average price of $5.68 and a two-hundred day moving average price of $4.58.

COMPASS Pathways (NASDAQ:CMPS) last posted its quarterly earnings data on Thursday, July 31st. The company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.01). Equities analysts predict that COMPASS Pathways PLC Sponsored ADR will post -2.33 EPS for the current year.

Analysts Set New Price Targets

Several analysts have recently weighed in on the company. BTIG Research boosted their price target on COMPASS Pathways from $7.00 to $14.00 and gave the stock a “buy” rating in a report on Monday, October 13th. HC Wainwright cut their target price on shares of COMPASS Pathways from $45.00 to $40.00 and set a “buy” rating on the stock in a research report on Monday, August 4th. Weiss Ratings restated a “sell (d-)” rating on shares of COMPASS Pathways in a research report on Wednesday, October 8th. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and set a $15.00 price target on shares of COMPASS Pathways in a research note on Friday, August 1st. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $16.57.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.